Get on Board: Inside the Board of Directors

If you would like to serve on a board, are already on a board, or work with a board, join us for Get on Board! The panelists are directors of both for-profit and nonprofit organization boards, and will address issues relating to service as directors, including the combinations of skills and experiences that boards are seeking, how to best position yourself for nonprofit or for-profit board candidacy, resources available to help you identify and take advantage of both paid and volunteer board opportunities, what it’s like to serve as a director on a board, and issues particular to women on boards. The discussion will be moderated by Ann Miller.

Panelists include:

  • Susan GrafBoard Chair & Audit Committee Chair, Finch Therapeutics
  • Minji KimPresident & CEO, Cross Border Partners, LLC
  • John SundyChief Medical Officer and Head of R&D, Seismic Therapeutic


Date and Time:  
June 21, 2023
6:00 - 9:00 PM

6:00-6:30: Registration, Refreshments, and Networking
6:30-8:00: Panel Discussion, Q&A
8:00-9:00: Optional Networking



Cambridge Consultants
2 Drydock 
Boston, MA 02210

Members: $0; Non-Members: $10

Download Flyer

Register Here


Thanks to our sponsor:

Cambridge Consultants, part of Capgemini Invent, develops breakthrough products and services, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 60 years, we’ve helped our clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. 

Speaker Bios

Susan Graf is an accomplished biopharma executive with 25+ years of deep operating and global leadership experience across pre-clinical entrepreneurial start-ups, mid-cap public biotech and large pharma. She is uniquely familiar with the opportunities and challenges faced by growing companies progressing from pre-clinical to clinical and onto commercial stage. Susan is well versed in public company governance, stemming from her time as a corporate officer, board member and board chair. Her companies have benefitted from her track record of value creating deals, strong industry connections, capital markets experience and strategic acumen. Susan currently chairs both the board the audit committee at Finch, a clinical stage microbiome company (Mar 2021 NASDAQ IPO). In her time at Finch, she ensured a smooth transition as a public company, oversaw a major strategic pivot and continues to serve as a thought partner to the CEO. For Kaleo Pharmaceuticals, Susan chairs the audit committee and serves on the compensation committee. Kaleo is a commercial stage company dedicated to building innovative solutions for serious and life-threatening medical conditions. Read More.

Dr. Minji Kim is a C-suite executive, advisor and company builder in life sciences with more than two decades of experience in corporate and business development, alliance management, commercial strategy, finance, operations, scientific research and company formation. She has extensive experience in start-up, mid-size public and private biotech companies in the US and China, and multinational pharmaceutical companies across broad therapeutic and technical areas, including oncology, CNS, ophthalmology, small molecule, biologics, medical device and digital medicine. Minji is currently President & CEO of Cross Border Partners, LLC, her consulting business to help start-ups, VCs and biopharmaceutical companies for corporate and program development strategies, business development and company formation efforts. She is also an independent board member of SK Biopharmaceuticals, a global commercial-stage biopharma company listed in KOSDAQ, where she serves ESG/Strategy, Nomination & Governance Committees. In addition, Minji is an advisor to a couple of US biotech companies as well as EIR of Yale Ventures. Read More.

Dr. Ann Miller spent 30+ years in the biopharma industry where she leveraged her breadth of commercialization expertise, clinical training, and commitment to team and capability building to make strategic choices and drive growth. Currently, she is a Director at Inovio Pharmaceuticals; previously, she was a Director at Puma Biotechnology and Allena Pharmaceuticals. Dr. Miller worked at Sanofi S.A. from 2012 until her retirement in September 2018, serving as Vice President of Marketing and Vice President of Global Marketing, Oncology Division. From 2009 to 2011, Dr. Miller served as Senior Vice President at Eisai Co., Ltd., leading the Primary Care and Specialty Business unit and then Pharmaceutical Services. Dr. Miller previously served in management roles of increasing responsibility at Amgen Inc. and Merck & Co., Inc. Dr. Miller received an M.D. from the Duke University School of Medicine and a B.A. in Chemistry, summa cum laude, from Duke University.  Currently, she is a mentor at the Founder’s Residency program at The Roux Institute at Northeastern University located in Portland and the Termeer Foundation.

John Sundy, MD, PhD, is a rheumatologist, allergist and immunologist with over 25 years of experience in academic medicine and the biotechnology industry. Currently, he is CMO and Head of R&D at Seismic Therapeutic. Prior to that he served as CMO at Pandion Therapeutics, which was acquired by Merck in 2021; and SVP and Inflammation Therapeutic Area Head at Gilead Sciences. There he led Gilead’s entry into inflammation and immunology and oversaw the clinical development of over a dozen new drug programs. Before moving to industry, John was a tenured Associate Professor of Medicine at Duke University and Associate Professor at the Duke-National University of Singapore Graduate Medical School. While at Duke he was instrumental in the Phase 1-3 development of Krystexxa which is approved for patients with refractory gout. In addition, he served as Associate Director of the Duke Clinical Research Institute and Director of Duke's Global Proof of Concept Research Unit Network in the US, Singapore and India. Read More.